Cold vs Hot Tumors Explained: Why the Tumor Microenvironment Determines Immunotherapy Success

Quick Answer

“Cold” and “hot” tumors describe how visible a cancer is to the immune system. Hot tumors have strong immune cell infiltration and are more likely to respond to immunotherapy. Cold tumors lack immune visibility and are more resistant.

However, recent research shows this is an oversimplification. Tumors exist along a spectrum of immune states, shaped not only by genetics (PD-L1, TMB, MSI-H) but also by the tumor microenvironment, including immune exclusion, metabolism, and stromal barriers.

Modern immunotherapy success depends on both tumor genetics and immune ecosystem structure.

Key Takeaways

• Tumors are not simply “cold” or “hot” but exist on an immune spectrum.
• Hot tumors usually respond better to PD-1/PD-L1 checkpoint inhibitors.
• Cold tumors often resist immunotherapy due to lack of immune infiltration.
• Immune-excluded tumors have immune cells at the edges but not inside.
• Immune-desert tumors lack meaningful immune presence entirely.
• Tumor microenvironment factors (stroma, metabolism, hypoxia) strongly influence response.
• PD-L1, TMB, and MSI-H explain only part of immunotherapy outcomes.
• Combination therapies can sometimes convert cold tumors into hot tumors.

What Are Cold and Hot Tumors?

Cancer immunotherapy works by activating the immune system—especially T cells—to recognize and destroy tumor cells. However, not all tumors are equally visible to the immune system.

Hot Tumors

Hot tumors are characterized by:

• High infiltration of CD8+ T cells
• Active immune signaling
• High PD-L1 expression
• Ongoing inflammatory activity

These tumors are more likely to respond to:

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4 inhibitors

Cold Tumors

Cold tumors are characterized by:

• Minimal T-cell infiltration
• Low immune activity
• Weak antigen presentation
• Immune evasion mechanisms

These tumors often respond poorly to immunotherapy alone.

Updated Scientific Understanding (2024 Systems-Level Research)

A 2024 large-scale immuno-oncology research (Signal Transduction and Targeted Therapy, 2024; DOI: s41392-024-01979-x) expands the traditional model of tumor immunity. Instead of a simple cold vs hot classification, tumors are better described using three immune architecture states:

1. Immune-Desert Tumors

These tumors lack immune cell infiltration entirely.

• Features: Very low CD8+ T-cell presence, poor antigen presentation, low inflammatory signaling, and often low tumor mutation burden.
• Clinical meaning: These tumors are among the most resistant to checkpoint inhibitors.

2. Immune-Excluded Tumors

These tumors contain immune cells, but they are blocked from entering the tumor core.

• Features: Immune cells accumulate at tumor borders, dense stromal barriers prevent infiltration, TGF-β signaling is often active, and abnormal tumor vasculature is present.
• Clinical meaning: These tumors are not truly “cold”—they are physically immune-restricted, and may respond to combination therapies targeting the tumor microenvironment.

3. Inflamed (Hot) Tumors

These tumors show strong immune infiltration but are suppressed by checkpoint pathways.

• Features: High CD8+ T-cell infiltration, elevated PD-L1 expression, and active immune signaling pathways.
• Clinical meaning: These tumors are most likely to respond to PD-1/PD-L1 blockade therapy.

Why the Cold vs Hot Model Is Incomplete

The 2024 systems immunology review highlights that tumor immune response depends on multiple interacting layers:

1. Tumor Genetics: TMB (mutation load), MSI-H (DNA repair deficiency), and Neoantigen burden.
2. Immune Checkpoints: PD-1 / PD-L1, CTLA-4, LAG-3, and TIGIT.
3. Tumor Microenvironment (TME): Fibroblast density, extracellular matrix stiffness, and immune cell exclusion zones.
4. Metabolic Environment: Hypoxia, glucose depletion, lactate accumulation, and acidic tumor pH.
5. Myeloid Suppression: Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs).

👉 Together, these factors determine whether immune cells can reach the tumor, survive inside it, and remain active long enough to kill cancer cells.

Why Some Cold Tumors Become Hot

One of the most important findings in modern immunotherapy research is that tumor immune states are not fixed. Cold tumors can be converted into hot tumors through:

• Radiotherapy (antigen release)
• Chemotherapy (immunogenic cell death)
• STING pathway activation
• Oncolytic viruses
• CTLA-4 + PD-1 combination therapy
• Tumor microenvironment reprogramming
• Metabolic intervention strategies

This process is now referred to as: Immune Reprogramming.

How This Relates to PD-L1, TMB, and MSI-H

Traditional biomarkers remain important, but they do not fully explain immunotherapy response.

• PD-L1: Measures immune suppression level.
• TMB: Measures mutation and neoantigen potential.
• MSI-H: Indicates DNA repair deficiency and high mutation generation.

Key Insight

Even when biomarkers suggest a high likelihood of response, immune exclusion, metabolic suppression, and stromal barriers can still prevent T-cell activation and tumor killing.

Real-World Clinical Interpretation

A patient’s immunotherapy response depends on whether:

1. Immune cells can enter the tumor (architecture)
2. Immune cells can recognize the tumor (antigens)
3. Immune cells remain active (microenvironment)

This explains why some PD-L1 high tumors fail to respond, some low-TMB tumors respond strongly, and some MSI-H tumors still show resistance.

The Future: Beyond Cold vs Hot

Modern immuno-oncology is shifting toward a Multi-Dimensional Tumor Classification. Future models integrate:

• PD-L1 expression
• Tumor mutation burden (TMB)
• MSI status
• Immune cell infiltration (TILs)
• Gene expression profiles
• Metabolic signatures
• Spatial immune architecture
• Myeloid suppression patterns

This creates a far more accurate prediction system than binary classification.

Clinical Takeaway: The most important insight from recent research is that immunotherapy response is determined not just by tumor genetics, but by the full tumor ecosystem—including immune access, metabolic conditions, and stromal structure. This is why modern oncology is moving toward combination immunotherapy + microenvironment modulation strategies rather than single-agent approaches.

Frequently Asked Questions

Are all hot tumors responsive to immunotherapy?

No. Even hot tumors can resist treatment due to additional suppressive mechanisms.

Can cold tumors be treated successfully?

Yes. Some cold tumors can be converted into hot tumors using combination therapies.

Is PD-L1 enough to predict response?

No. It is helpful but insufficient alone.

Which biomarker is best overall?

There is no single best biomarker. The strongest predictions come from combining PD-L1, TMB, MSI-H, and tumor microenvironment analysis.

Final Summary

The traditional “cold vs hot tumor” model remains useful for understanding immunotherapy response, but it is no longer sufficient on its own. Modern research shows that tumor immunity is governed by a complex interaction between:

• Genetic mutations
• Immune checkpoints
• Tumor microenvironment
• Metabolic conditions
• Spatial immune architecture

Understanding this full system is essential for predicting which patients will benefit from immunotherapy and for designing next-generation cancer treatments.

Reference:

1. Wu, B., Zhang, B., Li, B. et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Sig Transduct Target Ther 9, 274 (2024). https://doi.org/10.1038/s41392-024-01979-x